Annals of Surgical Oncology

, Volume 12, Issue 7, pp 511–512 | Cite as

Antitumor Vaccines: Of Mice and Men?

Editorial
  • 35 Downloads

Keywords

Trastuzumab Vaccine Therapy Immunogenic Tumor Major Histocompatibility Class Passive Immunotherapy 

References

  1. 1.
    Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7–17PubMedGoogle Scholar
  2. 2.
    Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639–48PubMedGoogle Scholar
  3. 3.
    Mocellin S, Mandrzzato S, Bronte V, Lise M, Nitti D. Part I: vaccines for solid tumors. Lancet Oncol 2004;5:681–9CrossRefPubMedGoogle Scholar
  4. 4.
    Dreno B, Nguyen JM, Khammari A, et al. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 2002;51:539–46Google Scholar
  5. 5.
    Harris JE, Ryan L, Hoover HC Jr, et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 2000;18:148–57PubMedGoogle Scholar
  6. 6.
    Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370–80Google Scholar
  7. 7.
    Mapura MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004;22:1136–51CrossRefPubMedGoogle Scholar
  8. 8.
    Viehl CT, Becker-Hapak M, Lewis JS, et al. A Tat fusion protein-based tumor vaccine for breast cancer. Ann Surg Oncol (in press)Google Scholar
  9. 9.
    Chazin VR, Kaleko M, Miller AD, Slamon DJ. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 1992;7:1859–66PubMedGoogle Scholar
  10. 10.
    Wadia JS, Dowdy SF. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev 2005;57:579–96CrossRefPubMedGoogle Scholar
  11. 11.
    Wilson NS, Villadangos JA. Regulation of antigen presentation and cross-presentation in the dendritic cell network: facts, hypothesis, and immunological implications. Adv Immunol 2005;86:241–305CrossRefPubMedGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 2005

Authors and Affiliations

  1. 1.Department of SurgeryNew York University School of MedicineNew York

Personalised recommendations